Humoral and cellular immune responses to SARS-CoV-2 vaccination across multiple vaccine platforms and liver disease types: an EASL registry multicentre prospective cohort study

Marjot, Thomas; Murray, Sam; Pose, Elisa; Lim, Zixiang; Londoño, María Carlota; Wittner, Melanie; Lütgehetmann, Marc; Hernández‐Gea, Virginia; Pagán, Juan Carlos García; Schaub, Golda M.; Duengelhoef, Paul Maria; Sterneck, Martina; Lohse, Ansgar W.; Trivedi, Palak; Bhandal, Khushpreet; Mullish, Benjamin H.; Manousou, Pinelopi; Burra, Patrizia; Facchetti, F.; Dobson, Susan L; Deeks, Alexandra; Turtle, Lance; Klenerman, Paul; Dunachie, Susanna; Ginès, Pere; Iavarone, M.; Wiesch, Julian Schulze zur; Russo, Francesco; Barnes, Eleanor

doi:10.1016/s0168-8278(22)00515-3

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…7,[77][78][79][80][81] Prior studies have demonstrated that vaccination was overall safe in patients with CLD, though more emerging data indicates concerns over markedly reduced or rapidly waning immune response for patients with cirrhosis. 8,[82][83][84] In addition, some concern has been raised about the possibility of vaccine induced AIH. Some case reports indicate not only a presentation of acute hepatitis following mRNA vaccination similar to AIH, but also presented liver biopsy samples from the patients showing panlobular immune infiltrate with activated cytotoxic CD8 T cells.…”

Section: Clinical Outcomes Of Covid-19 In Patients With Cld and Cirrh...mentioning

confidence: 99%

SARS-CoV-2 Infection and Liver Disease: A Review of Pathogenesis and Outcomes

et al. 2022

Self Cite

View full text Add to dashboard Cite

The impact of the coronavirus disease 2019 (COVID-19) pandemic has been immense, and it continues to have lasting repercussions. While the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus primarily infects the respiratory system, other organ systems are affected, including the liver. Scientific knowledge on the role of SARS-CoV-2 infection and liver injury has evolved rapidly, with recent data suggesting specific hepatotropism of SARS-CoV-2. Moreover, additional concerns have been raised in regard to long-term liver damage, related to emerging cases of post-COVID-19 cholangiopathy and chronic cholestasis. Great effort has also been focused on studying how specific subpopulations with chronic medical conditions might be disproportionately impacted by COVID-19. One such population includes individuals with chronic liver disease (CLD) and cirrhosis, with an expanding body of research indicating these patients being particularly susceptible to adverse outcomes. In this review, we provide an updated summary on the current pathogenesis and mechanism of liver injury in the setting of SARS-CoV-2 infection, the association between health outcomes and SARS-CoV-2 infection in patients with CLD, and the unique consequences of the COVID-19 pandemic on the routine care of patients with CLD.

show abstract